N4 Pharma Nuvec showing fantastic results (Interview)

N4 Pharma plc (LON:N4P) CEO Nigel Theobald joins DirectorsTalk to discuss its operations update. Nigel explains what is involved in the Material Transfer Agreements that have been announced, whether these are exclusive, how the work done under the MTA and subsequent relationships may negate the need for the Company to do its own proof of concept work and what else investors can expect over the coming months.

N4 Pharma, are a specialist pharmaceutical company developing a novel silica nanoparticle delivery system for vaccines and therapeutics for licensing to pharmaceutical and biotech partners. This nanoparticle has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines.

You might also enjoy reading  N4 Pharma's proof of concept work is extremely encouraging

Share this interview

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on whatsapp
N4 Pharma - Nigel Theobald
N4 Pharma Nuvec showing fantastic results (Interview)

Other Interviews

More News

Ask your questions

Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

I have questions